Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Munich - Delayed Quote • EUR Esperion Therapeutics Inc (0ET.MU) Follow Compare 0.8932 0.0000 (0.00%) As of 8:00:58 AM GMT+2. Market Open. Comparisons Indicators Technicals Corporate Events Draw List View Grid View Detach Attach No Tool Measure UNDO Redo All All Favorites Text Statistics Technicals Fibonacci Markings Lines Annotation Arrow Line Horizontal Vertical Rectangle Trend Line Measurement Line Average Line Callout Channel Check Continuous Crossline Elliott Wave Ellipse Doodle Fib Projection Fib Arc Fib Fan Fib Time Zone Focus Gann Fan Gartley Heart Pitchfork Quadrant Lines Ray Regression Line Fib Retracement Star Speed Resistance Arc Speed Resistance Line Time Cycle Tirone Levels Volume Profile Cross Magnet Clear All Drawings Restore Default Parameters Loading Chart for 0ET.MU 1D 5D 1M 3M 6M YTD 1Y 5Y All Date Range 1 min Recent News: 0ET.MU View More All News Press Releases SEC Filings Esperion to Host R&D Day to Highlight Cardiometabolic Pipeline Innovation and Next-Generation Therapeutics on April 24, 2025 Esperion Therapeutics (ESPR) Down 15.8% Since Last Earnings Report: Can It Rebound? Esperion Appoints Robert E. Hoffman to Board of Directors Esperion to Participate in 24th Annual Needham Virtual Healthcare Conference ESPR to Study Bempedoic Acid in Pediatric Familial Hypercholesterolemia Esperion Aligns with U.S. Food and Drug Administration to Initiate Phase 3 Clinical Trials of Bempedoic Acid in Pediatric Heterozygous and Homozygous Familial Hypercholesterolemia ESPR's Q4 Loss Narrower Than Expected, Revenues Increase Y/Y Q4 2024 Esperion Therapeutics Inc Earnings Call Esperion Therapeutics (ESPR) Reports Q4 Loss, Lags Revenue Estimates Esperion Therapeutics: Q4 Earnings Snapshot Esperion Reports Fourth Quarter and Full Year 2024 Financial Results